These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31202558)

  • 1. [Dose reassessment: An answer to the high cost of drugs used in oncology?].
    Levêque D
    Bull Cancer; 2019 Sep; 106(9):719-724. PubMed ID: 31202558
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 4. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
    Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
    J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brigatinib (Alunbrig) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e72-e73. PubMed ID: 29667950
    [No Abstract]   [Full Text] [Related]  

  • 7. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O; Hjalte F; Taylor M
    Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WEE1 Kinase As a Target for Cancer Therapy.
    Mueller S; Haas-Kogan DA
    J Clin Oncol; 2015 Oct; 33(30):3485-7. PubMed ID: 26215953
    [No Abstract]   [Full Text] [Related]  

  • 11. Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.
    Chen CT; Kesselheim AS
    J Oncol Pract; 2017 Jun; 13(6):352-355. PubMed ID: 28445102
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 13. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 14. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 15. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 16. [Funding of anticancer drugs in France].
    Levêque D
    Bull Cancer; 2018 Feb; 105(2):200-203. PubMed ID: 29395039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 18. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole AL; Dusetzina SB
    Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing oncology products.
    Penna P
    Manag Care Interface; 2005 Jun; 18(6):41-2. PubMed ID: 16018298
    [No Abstract]   [Full Text] [Related]  

  • 20. Hopes for eliminating cancer climb with every new breakthrough in oncology.
    Haugh R
    Hosp Health Netw; 2005 Oct; 79(10):46-8, 50, 1. PubMed ID: 16334003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.